HEALTH● LOWAug 17 · Aug 17, 2026, 8:28 AM
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
Seeking Alpha Tech
A company's drug, Vyvgart, has met key trial endpoints for autoimmune myositis, indicating progress in its development for this condition. This represents a significant step in medical research for autoimmune diseases.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH27m agoChina cancer patient who inspired hit film hopes to stop treatment after 35,000 pills over 2 decadesSouth China Morning PostHEALTH27m agoHong Kong elderly urged to stay indoors as air pollution spikes to serious levelsSouth China Morning PostHEALTH52m agoA greying population, a strained care systemThe HinduHEALTH2h agomRNA cancer vaccine helps reduce the chances of melanoma tumors returning4029tv.com · United States